The Marriage between Nanotechnology and Stem Cells Secretome for COPD.
Nanoparticles
chronic obstructive pulmonary disease
drug delivery
mesenchymal stem cells
regenerative medicine
secretome
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
09
2021
revised:
01
12
2021
accepted:
30
12
2021
pubmed:
22
3
2022
medline:
20
7
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Chronic Obstructive Pulmonary Disease (COPD) is a disorder characterized by narrow alveoli as a result of emphysema. As such, there is no treatment to cure this disorder completely, and existing drugs only delay the progression of the disease. In recent years, the stem cell secretome as a drug is remarkably used as a regenerative therapy. In particular, cell-free therapy approaches offer great opportunities for the treatment of COPD. However, a few issues, such as the delivery of stem cell secretome as a drug to the alveolar region, have obstructed their application in clinical scales. To address these challenges, a combination of stem-cells secretome as a drug with nanotechnology could be a smart solution. We suggest that the combinational approach of delivering nanoparticles loaded with stem cell secretome could be a translational medicine approach for the successful outcome of COPD.
Identifiants
pubmed: 35306993
pii: CDT-EPUB-121672
doi: 10.2174/1389450123666220318102138
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-685Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.